Article
Rheumatology
Alexis Ogdie, Mei Liu, Meghan Glynn, Kelechi Emeanuru, Leslie R. Harrold, Sven Richter, Benoit Guerette, Philip J. Mease
Summary: The study found that apremilast monotherapy is an effective option for patients with oligoarticular PsA. Apremilast initiators experienced greater disease activity improvements at follow-up compared to MTX initiators.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Rheumatology
Arianna Damiani, Francesca Bartoli, Giovanni Pacini, Davide Carboni, Silvia Bellando Randone, Ginevra Fiori, Marco Matucci-Cerinic, Serena Guiducci
Summary: This study investigates the remission persistency after lengthening the time between golimumab injections in patients with inflammatory joint diseases. The results show that golimumab lengthening is safe and successfully maintains remission. In patients who experienced a flare after lengthening, the standard regimen promptly restored remission.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2023)
Article
Rheumatology
Andreas Kerschbaumer, Zaida Iasha Rivai, Josef S. Smolen, Daniel Aletaha
Summary: This study analyzed the response differences in patients with rheumatoid arthritis receiving placebo treatment, comparing those who continued background therapy with methotrexate (MTX) and those without any disease modifying antirheumatic drugs (DMARDs). The results showed that placebo responses were higher in patients who continued MTX background therapy, suggesting a more consequent intake of background therapy during the trial period.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Medicine, General & Internal
Nicolino Ruperto, Hermine Brunner, Olga Synoverska, Tracy Ting, Carlos Abud Mendoza, Alberto Spindler, Yulia Vyzhga, Katherine Marzan, Lyudmila Grebenkina, Irit Tirosh, Lisa Imundo, Rita Jerath, Daniel J. Kingsbury, Betul Sozeri, Sheetal S. Vora, Sampath Prahalad, Elena Zholobova, Yonatan Butbul Aviel, Vyacheslav Chasnyk, Melissa Lerman, Kabita Nanda, Heinrike Schmeling, Heather Tory, Yosef Uziel, Diego O. Viola, Holly B. Posner, Keith S. Kanik, Ann Wouters, Cheng Chang, Richard Zhang, Irina Lazariciu, Ming-Ann Hsu, Ricardo M. Suehiro, Alberto Martini, Daniel J. Lovell
Summary: The trial showed that tofacitinib is an effective treatment for patients with polyarticular course JIA. New oral therapies are particularly relevant for children and adolescents, who might prefer to avoid injections.
Article
Medicine, General & Internal
Raymond Hang Wun Li, Sue Seen Tsing Lo, Kristina Gemzell-Danielsson, Carol Ho Yi Fong, Pak Chung Ho, Ernest Hung Yu Ng
Summary: This study found that co-administration of oral piroxicam 40 mg with levonorgestrel improved the efficacy of emergency contraception. The use of piroxicam could be considered in clinical settings where levonorgestrel emergency contraception is the chosen option.
Article
Rheumatology
Dzenan Masic, Kristian Stengaard-Pedersen, Brian Bridal Logstrup, Kim Horslev-Petersen, Merete Lund Hetland, Peter Junker, Mikkel ostergaard, Christian Ammitzboll, Soren Moller, Robin Christensen, Torkell Ellingsen
Summary: In patients with rheumatoid arthritis, there were no significant differences in lipid level changes between those treated with adalimumab plus methotrexate and those treated with placebo plus methotrexate over a 1-year period. The study suggests that both treatment strategies have similar effects on lipid levels in early and treatment-naive RA patients.
RHEUMATOLOGY INTERNATIONAL
(2021)
Article
Rheumatology
Florenzo Iannone, Ennio G. Favalli, Roberto Caporali, Salvatore D'Angelo, Francesco Paolo Cantatore, Piercarlo Sarzi-Puttini, Rosario Foti, Fabrizio Conti, Antonio Carletto, Elisa Gremese, Alberto Cauli, Roberta Ramonda, Adalgisa Palermo, Oscar Epis, Marta Priora, Francesca Bergossi, Bruno Frediani, Fausto Salaffi, Giuseppe Lopalco, Fabio Cacciapaglia, Antonio Marchesoni, Martina Biggioggiero, Serena Bugatti, Silvia Balduzzi, Antonio Carriero, Addolorata Corrado, Sara Bongiovanni, Alessia Benenati, Francesca Miranda, Elena Fracassi, Daniela Perra, Gianfranco Ferraccioli, Giovanni Lapadula
Summary: The study evaluated the clinical effectiveness of golimumab in biologic inadequate responder patients with RA, SpA, and PsA. Golimumab showed similar effectiveness in SpA and PsA patients, but was less effective in multi-failure RA patients, especially as monotherapy. Male patients had better outcomes.
Article
Medicine, General & Internal
Athimalaipet Ramanan, Pierre Quartier, Nami Okamoto, Ivan Foeldvari, Alberto Spindler, Sarka Fingerhutova, Jordi Anton, Zhongkai Wang, Gabriella Meszaros, Joana Araujo, Ran Liao, Stuart Keller
Summary: Baricitinib demonstrated good efficacy and acceptable safety in the treatment of polyarticular juvenile idiopathic arthritis, extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.
Article
Gastroenterology & Hepatology
Brian G. Feagan, Bruce E. Sands, William J. Sandborn, Matthew Germinaro, Marion Vetter, Jie Shao, Shihong Sheng, Jewel Johanns, Julian Panes
Summary: This study compared the efficacy of combination therapy with guselkumab and golimumab to monotherapy for ulcerative colitis, and found that combination therapy achieved a higher clinical response rate at 12 weeks. However, these findings need to be confirmed in larger trials.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Rheumatology
Louise Linde, Lykke M. Ornbjerg, Stylianos Georgiadis, Simon H. Rasmussen, Ulf Lindstrom, Johan Askling, Brigitte Michelsen, Daniela Di Giuseppe, Johan K. Wallman, Bjorn Gudbjornsson, Thorvardur Jon Love, Dan C. Nordstrom, Timo Yli-Kerttula, Lucie Nekvindova, Jiri Vencovsky, Florenzo Iannone, Alberto Cauli, Anne Gitte Loft, Bente Glintborg, Karin Laas, Ziga Rotar, Matija Tomsic, Gary J. Macfarlane, Burkhard Moller, Marleen van de Sande, Catalin Codreanu, Michael J. Nissen, Merih Birlik, Sukran Erten, Maria J. Santos, Elsa Vieira-Sousa, Merete L. Hetland, Mikkel Ostergaard
Summary: In bio-naive patients with PsA initiating a TNF inhibitor (TNFi), baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission and moderate response at 6 months, as well as drug retention at 12 months were identified, indicating potential generalizability from country to disease level.
Article
Rheumatology
Michelle L. M. Mulder, Johanna E. Vriezekolk, Tamara W. van Hal, Lieke M. Nieboer, Nathan den Broeder, Elke M. G. J. de Jong, Alfons A. den Broeder, Frank H. J. van den Hoogen, Philip S. Helliwell, Mark H. Wenink
Summary: The combination therapy of methotrexate plus leflunomide leads to greater improvement in disease activity for patients with psoriatic arthritis compared to methotrexate monotherapy. However, the combination therapy is less well-tolerated.
LANCET RHEUMATOLOGY
(2022)
Article
Rheumatology
Maria C. Cid, Sebastian H. Unizony, Daniel Blockmans, Elisabeth Brouwer, Lorenzo Dagna, Bhaskar Dasgupta, Bernhard Hellmich, Eamonn Molloy, Carlo Salvarani, Bruce C. Trapnell, Kenneth J. Warrington, Ian Wicks, Manoj Samant, Teresa Zhou, Lara Pupim, John F. Paolini
Summary: This study evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission in patients with giant cell arteritis. The results showed that mavrilimumab plus prednisone was superior to placebo plus prednisone in terms of time to flare and sustained remission.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Oncology
Matthew J. Matasar, Marcelo Capra, Muhit Ozcan, Fangfang Lv, Wei Li, Eduardo Yanez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Ross Baker, Igor Bondarenko, Qingyuan Zhang, Jifeng Feng, Klaus Geissler, Mihaela Lazaroiu, Guray Saydam, Arpad Szomor, Krimo Bouabdallah, Rinat Galiulin, Toshiki Uchida, Lidia Mongay Soler, Anjun Cao, Florian Hiemeyer, Aruna Mehra, Barrett H. Childs, Yuankai Shi, Pier Luigi Zinzani
Summary: Copanlisib plus rituximab significantly improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma compared with placebo plus rituximab, with the most common grade 3-4 adverse events being hyperglycemia and hypertension.
Article
Rheumatology
Matthew L. Thomas, Gavin Shaddick, Rachel Charlton, Charlotte Cavill, Richard Holland, Florenzo Iannone, Giovanni Lapadula, Simona Lopriore, Jakub Zavada, Michal Uher, Karel Pavelka, Lenka Szczukova, Prodromos Sidiropoulos, Irini Flouri, Alexandros Drosos, Burkhard Moller, Michael J. Nissen, Rudiger B. Mueller, Almut Scherer, Neil McHugh, Alison Nightingale
Summary: Combination therapy of a TNFi with a csDMARD does not appear to affect improvement of disease activity or HAQ versus TNFi monotherapy, but it may improve TNFi drug survival.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Immunology
Yasmina Chouik, Domitille Erard, Hassan Demian, Thomas Schulz, Tessa Mazard, Kerstin Hartig-Lavie, Teresa Antonini, Jean-Yves Mabrut, Kayvan Mohkam, Agnes Rode, Philippe Merle
Summary: Atezolizumab/Bevacizumab combination therapy can achieve complete pathological response in advanced unresectable HCC, providing a potential option for liver transplantation.
FRONTIERS IN IMMUNOLOGY
(2023)
Letter
Rheumatology
Ronald F. van Vollenhoven, Sander W. Tas, Michael T. Nurmohamed
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Marijke van den Dikkenberg, Nathalie Luurssen-Masurel, Tjallingius Martijn Kuijper, Marc-Redwart Kok, Johanna Maria Wilhelmina Hazes, Pascal Hendrik Pieter de Jong, Deirisa Lopes-Barreto, Angelique Elisabeth Adriana Maria Weel-Koenders
Summary: This systematic review aims to evaluate the effects of disease-modifying antirheumatic drugs (DMARDs) on patient-reported outcomes in rheumatoid arthritis. The results showed that DMARDs reduce the burden of pain, fatigue, and activity limitation compared to placebo and methotrexate.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibanez, Tatiana Korotaeva, Frederic Lavie, Wim Noel, Michael T. Nurmohamed, Petros P. Sfikakis, Mohamed Sharaf, Elke Theander, Josef S. Smolen
Summary: This study evaluated the real-world persistence and effectiveness of the IL-12/23 inhibitor ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years. The results showed that the proportion of patients still on their initial treatments after 3 years was similar with ustekinumab and TNFi, but ustekinumab had a lower rate of adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
A. B. Blanken, M. Korteweg, L. van Boheemen, R. F. van Vollenhoven, M. T. Nurmohamed, C. J. van der Laken
Summary: The study aimed to investigate the performance and factors of influence of optical spectral transmission (OST) imaging as a new technique for measuring joint inflammation in rheumatoid arthritis (RA). The results showed significant differences in OST scores between RA patients and the control group, and moderate correlations between OST scores and ultrasound and clinical disease activity.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Medicine, Research & Experimental
P. N. d'Ailly, C. Deugd, N. W. L. Schep, T. M. Kuijper, M. R. Kok, A. Willemze, J. H. Coert, P. H. P. de Jong, W. K. Lam-Tse, A. H. M. van der Helm-van Mil, I. Tchetverikov, A. E. A. M. Weel-Koenders, R. J. Bisoendial
Summary: This study aims to evaluate the effect of arthroscopic synovectomy and intra-articular corticosteroid injections (IACSI) on wrist function in patients with therapy-resistant rheumatoid arthritis (RA) and psoriatic arthritis (PsA). A prospective randomized controlled trial will be conducted, recruiting 80 eligible patients who will be randomly assigned to two different treatment groups. The primary outcome measure is the improvement of wrist function.
Review
Rheumatology
M. Sobejana, M. van der Esch, J. van den Hoek, G. Kitas, M. van der Leeden, M. T. Nurmohamed, G. S. Metsios
Summary: In addition to DMARD treatment, exercise is increasingly promoted in patients with RA, but few studies have investigated the combined effects of these interventions on disease activity. This scoping review summarized the evidence on whether a combined effect can be detected in studies where exercise intervention was performed in addition to DMARD treatment. Eleven studies were included, and although some showed significant reductions in disease activity outcomes for the exercise + medication group compared with the medication-only group, most studies had weak methodological quality.
CURRENT RHEUMATOLOGY REPORTS
(2023)
Article
Economics
Fiona Koster, Marc R. Kok, Jaco van der Kooij, Geeke Waverijn, Angelique E. A. M. Weel-Koenders, Deirisa Lopes Barreto
Summary: Time-driven activity-based costing (TDABC) using fuzzy logic (FL-TDABC) provides a more precise and efficient estimate of healthcare cycle costs, considering the subjective nature of time estimates. The FL-TDABC methodology estimated the annual costs of the rheumatoid arthritis (RA) care cycle to be euro1497 per patient, with a 22% cost variation. The main cost drivers were consultations with rheumatologists and pharmacy costs. FL-TDABC offers insights for transitioning from a volume-based system to a value-based healthcare (VBHC) system.
PHARMACOECONOMICS-OPEN
(2023)
Article
Rheumatology
Abdullah Ali Hadi Almayali, Maarten Boers, Linda Hartman, Daniela Opris, Reinhard Bos, Marc R. Kok, Jose A. P. Da Silva, Ed Griep, Ruth Klaasen, Cornelia F. Allaart, Paul Baudoin, Hennie G. Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol Masaryk, Willem Lems, Yvo Smulders, Maurizio Cutolo, Marieke M. ter Wee
Summary: The GLORIA trial investigated the effects of prednisolone 5 mg/day as an addition to standard care for 2 years in elderly patients with rheumatoid arthritis. Tapering off prednisolone moderately increased disease activity and risk of flare, but did not show evidence of adrenal insufficiency.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
J. van den Hoek, M. Sobejana, F. van Nes, G. Metsios, G. Kitas, M. van der Leeden, M. T. Nurmohamed, M. van der Esch
Summary: The objective of this study was to gain insight into the perceptions and experiences of patients with rheumatoid arthritis and a high cardiovascular disease risk (CVD-RA) undergoing an exercise intervention. The study analyzed data from six patients through face-to-face interviews and identified seven themes related to perceptions and experiences. The findings highlighted the importance of being viewed as a person and feeling safe.
RHEUMATOLOGY INTERNATIONAL
(2023)
Article
Rheumatology
F. R. Kasiem, M. R. Kok, J. J. Luime, I. Tchetverikov, K. Wervers, L-a. Korswagen, N. Denissen, Y. P. M. Goekoop-Ruiterman, M. van Oosterhout, F. Fodili, J. M. W. Hazes, M. Vis
Summary: This study aimed to assess whether the health-related quality of life (HRQoL) of patients who reached musculoskeletal low disease activity can be further improved by achieving remission in psoriasis. The results showed that the majority of patients with musculoskeletal low disease activity and active psoriasis had good HRQoL after one year. However, a proportion of these patients still experienced considerable skin burden.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2023)
Article
Rheumatology
Fiona Koster, Pieter L. H. Bakx, Marc R. Kok, Deirisa Lopes Barreto, Angelique E. A. M. Weel-Koenders
Summary: The prevalence of multimorbidity is increasing among patients with rheumatoid arthritis (RA) and is associated with worse outcomes. This study examines the importance of a multidisciplinary, integrated approach in managing multimorbid patients and assesses the association between expenditures and multimorbidity using real-life data.
RHEUMATOLOGY INTERNATIONAL
(2023)
Article
Rheumatology
Jimmy Wiegel, Bart F. Seppen, Michael T. Nurmohamed, Marieke M. ter Wee, Wouter H. Bos
Summary: Routine collection of ePROs prior to consultations can improve clinical care, but a low response rate may limit its benefits. This study found that patients between 55 and 73 years of age and with higher socio-economic status were more likely to complete the ePROs, while patients living in urban areas had lower odds.
RHEUMATOLOGY INTERNATIONAL
(2023)
Article
Rheumatology
Bart F. F. Seppen, Jimmy Wiegel, Michael T. T. Nurmohamed, Wouter H. H. Bos, Marieke M. M. ter Wee
Summary: Telemonitoring disease activity with ePROs can reduce rheumatic care workload by cutting down on outpatient clinic visits, but low adherence to reporting ePROs is common. This study aimed to identify facilitators and barriers to weekly monitoring of disease activity. Focus group discussions were held with patients who had recently participated in telemonitoring studies using a smartphone app for ePRO completion. Thematic analysis revealed five themes related to adherence: questionnaire frequency, discussing results, physical consultations, patient insight, and user experience. Both barriers and facilitators were found within these themes. The results suggest that maximizing the perceived benefits of completing ePROs and tailoring their frequency based on patients' disease activity or preference, along with training clinicians to discuss the completed ePROs, may improve adherence.
RHEUMATOLOGY INTERNATIONAL
(2023)
Article
Rheumatology
Reinder Raadsen, Romy Hansildaar, Lianne C. Pouw, Femke Hooijberg, Laura Boekel, Gerrit Jan Wolbink, Arno W. R. van Kuijk, Michael T. Nurmohamed
Summary: This study evaluates the cardiovascular disease risk and prevalence of risk factors in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (SpA). The results show that the traditional cardiovascular risk factors are significantly elevated in these patients compared to healthy controls. However, after adjusting for traditional risk factors, the cardiovascular risk was not increased in these patients.
Article
Rheumatology
Fiona Koster, Deirisa Lopes Barreto, Sandhya C. Nair, Marc R. Kok, Angelique E. A. M. Weel-Koenders
Summary: The study aimed to establish a validated process map of the care cycle for patients with Rheumatoid Arthritis (RA) in order to improve the quality of care and identify areas for improvement. By systematically documenting activities and resources and conducting interviews with medical staff, a comprehensive process map was created. This approach increased transparency, optimized care delivery, and resulted in improvement actions on both outcome and process levels.
RHEUMATOLOGY INTERNATIONAL
(2023)